AIM:EVG

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Evgen Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVG is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: EVG's weekly volatility has decreased from 20% to 10% over the past year.


Market Performance


7 Day Return

24.1%

EVG

-1.3%

GB Biotechs

-0.4%

GB Market


1 Year Return

29.8%

EVG

25.5%

GB Biotechs

-10.1%

GB Market

Return vs Industry: EVG exceeded the UK Biotechs industry which returned 25.5% over the past year.

Return vs Market: EVG exceeded the UK Market which returned -10.1% over the past year.


Shareholder returns

EVGIndustryMarket
7 Day24.1%-1.3%-0.4%
30 Day-5.3%-5.5%13.4%
90 Day-30.2%2.8%6.4%
1 Year29.8%29.8%26.0%25.5%-6.5%-10.1%
3 Year-40.2%-40.2%5.0%3.7%1.5%-10.9%
5 Year-65.6%-65.6%35.8%33.2%27.4%-1.6%

Long-Term Price Volatility Vs. Market

How volatile is Evgen Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evgen Pharma undervalued compared to its fair value and its price relative to the market?

3.09x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EVG is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: EVG is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVG is good value based on its PB Ratio (3.1x) compared to the GB Biotechs industry average (5.2x).


Next Steps

Future Growth

How is Evgen Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

19.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if EVG's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if EVG's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EVG's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Evgen Pharma performed over the past 5 years?

1.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVG is currently unprofitable.

Growing Profit Margin: EVG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EVG is unprofitable, but has reduced losses over the past 5 years at a rate of 1.4% per year.

Accelerating Growth: Unable to compare EVG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: EVG has a negative Return on Equity (-64.58%), as it is currently unprofitable.


Next Steps

Financial Health

How is Evgen Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: EVG's short term assets (£4.8M) exceed its short term liabilities (£653.0K).

Long Term Liabilities: EVG has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: EVG is debt free.

Reducing Debt: EVG currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EVG has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 12.4% each year.


Next Steps

Dividend

What is Evgen Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVG's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Huw Jones (60 yo)

0.83

Tenure

Dr. Huw Jones, BSc, Ph.D. serves as Chief Executive Officer at Evgen Pharma plc since 2020. He has been Chief Executive Officer at Chronos Therapeutics Ltd. since December 2012 and serves as its Director. ...


Leadership Team

NamePositionTenureCompensationOwnership
Richard Moulson
CFO & Executive Director3.83yrsUK£85.40k0.030%
£ 4.1k
Huw Jones
Chief Executive Officer0.83yrno datano data
Liz Jenkins
Regulatory Consultantno datano datano data
Thomas Morris
Consultant & Medical Advisor of Oncology3.67yrsno datano data
Albena Dinkova-Kostova
Independent Scientific Advisor2.83yrsno datano data
Giovanni Mann
Independent Scientific Advisor2.83yrsno datano data

2.8yrs

Average Tenure

Experienced Management: EVG's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Moulson
CFO & Executive Director3.83yrsUK£85.40k0.030%
£ 4.1k
Susan Foden
Non-Executive & Senior Independent Directorno dataUK£26.50kno data
Barry Clare
Non-Executive Chairman3.92yrsUK£41.67k0.31%
£ 42.2k
Alan Barge
Independent Non-Executive Director5.08yrsUK£22.50kno data
Susan Clement-Davies
Independent Non-Executive Director2yrsUK£26.17kno data

3.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: EVG's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.


Top Shareholders

Company Information

Evgen Pharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evgen Pharma plc
  • Ticker: EVG
  • Exchange: AIM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£13.455m
  • Shares outstanding: 137.30m
  • Website: https://www.evgen.com

Number of Employees


Location

  • Evgen Pharma plc
  • The Colony
  • Altrincham Road
  • Wilmslow
  • Cheshire
  • SK9 4LY
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EVGAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2015
8EVDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2015

Biography

Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synt...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/28 18:32
End of Day Share Price2020/11/27 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.